Methods for regulating endogenous production of lactoferrin and sub-peptides thereof

Abstract

The present disclosure relates to the composition of one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for upregulating production of lactoferrin or a sub-peptide of lactoferrin. Embodiments of the present disclosure can be used as a therapy or a treatment of adhesions or scarring.

I claim: 
     
         1 . A recombinant virus vector (RVV) comprising a virus with a gene insert that induces a target cell to increase production of human lactoferrin protein. 
     
     
         2 . The RVV of  claim 1 , wherein the human lactoferrin protein has an amino acid sequence of SEQ ID No. 1. 
     
     
         3 . The RVV of  claim 1 , wherein the RVV is of a genus that is one of a flavivirus, an influenza, an enterovirus, a rotavirus, a rubellavirus, a rubivirus, a morbillivirus, an orthopoxvirus, a varicellovirus, a dependoparvovirus, an alphabaculovirus, a betabaculovirus, a deltabaculovirus, a gammabaculovirus, a mastadenovirus, a simplexvirus, a varicellovirus, a cytomegalovirus, and combinations thereof. 
     
     
         4 . The RVV of  claim 1 , wherein the gene insert codes for a sub-peptide of the human lactoferrin protein that is between about 5 to about 710 amino acids. 
     
     
         5 . The RVV of  claim 4 , wherein the sub-peptide is a linear sequential sub-peptide. 
     
     
         6 . A method of making an agent/target cell complex, the method comprising a step of administering a recombinant virus vector (RVV) to a target cell for forming an agent/target cell complex, wherein the agent/target cell complex causes the target cell to increase a production of the human lactoferrin protein. 
     
     
         7 . A method of making an agent/target cell complex, wherein the human lactoferrin protein is a sub-peptide of human lactoferrin protein that is between about 5 to about 710 amino acids. 
     
     
         8 . The method of  claim 6 , wherein the target cell is one or more of an adrenal gland cell; a B cell; a bile duct cell; a chondrocyte; a cochlear cell; a corneal cell; an endocardium cell; an endometrial cell; an endothelial cell; an epithelial cell; an eosinophil; a fibroblast; a hair follicle cell; a hepatocyte; a lymph node cell; a macrophage; a mucosal cell; a myocyte; a neuron; a glomeruli cell; an optic nerve cell; an osteoblast; an ovarian tissue cell; a pancreatic islet beta cell; a pericardium cell; a platelet; a red blood cell (RBC); a retinal cell; a scleral cell; a Schwann cell; a T cell; a testicular tissue cell; a thyroid gland cell; an uveal cell; and combinations thereof 
     
     
         9 . A pharmaceutical agent comprising:
 a. an agent that upregulates production of a human lactoferrin protein;   b. a pharmaceutically acceptable carrier; and/or   c. an excipient.   
     
     
         10 . The pharmaceutical agent of  claim 9 , wherein the pharmaceutical agent is in a solid form or a liquid form. 
     
     
         11 . The pharmaceutical agent of  claim 9 , wherein the wherein the human lactoferrin protein is a sub-peptide of human lactoferrin protein that is between about 5 to about 710 amino acids. 
     
     
         12 . A method of treating a condition, the method comprising a step of administering to a subject a therapeutically effective amount of an agent that upregulates the production of human lactoferrin protein. 
     
     
         13 . The method of  claim 12 , wherein the wherein the human lactoferrin protein is a sub-peptide of human lactoferrin protein that is between about 5 to about 710 amino acids. 
     
     
         14 . The method according to  claim 12 , wherein the condition is the development of one or more adhesions. 
     
     
         15 . The method according to  claim 12 , wherein the condition is scarring. 
     
     
         16 . The method according to  claim 12 , wherein the step of administering occurs by an intravenous route, an intramuscular route, an intraperitoneal route, an intrathecal route, an intravesical route, a topical route, an intranasal route, a transmucosal route, a pulmonary route, and combinations thereof. 
     
     
         17 . The method according to  claim 12 , wherein the therapeutically effective amount is between about 10 to about 1×10 16  TCID 50 /kg of the patient's body weight. 
     
     
         18 . The method according to  claim 12 , wherein the therapeutically effective amount is between about 10 to about 1×10 16  total particles of the agent.